Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:SUPN
- CUSIP: 86845910
- Web: www.supernus.com
Capitalization:- Market Cap: $1.9291 billion
- Outstanding Shares: 50,699,000
Average Prices:- 50 Day Moving Avg: $44.56
- 200 Day Moving Avg: $37.95
- 52 Week Range: $17.25 - $50.05
P/E:- Trailing P/E Ratio: 19.20
- Foreward P/E Ratio: 22.14
- P/E Growth: 1.36
Sales & Book Value:- Annual Revenue: $252.59 million
- Price / Sales: 7.38
- Book Value: $4.52 per share
- Price / Book: 8.13
Profitability:- EBIDTA: $82.36 million
- Net Margins: 41.10%
- Return on Equity: 30.73%
- Return on Assets: 19.48%
Debt:- Debt-to-Equity Ratio: 0.01%
- Current Ratio: 1.94%
- Quick Ratio: 1.74%
Misc:- Average Volume: 705,105 shs.
- Beta: 1.3
- Short Ratio: 7.53
Frequently Asked Questions for Supernus Pharmaceuticals (NASDAQ:SUPN)
What is Supernus Pharmaceuticals' stock symbol?
Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."
How were Supernus Pharmaceuticals' earnings last quarter?
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) issued its quarterly earnings results on Wednesday, August, 2nd. The company reported $0.32 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.24 by $0.08. The company had revenue of $75.83 million for the quarter, compared to the consensus estimate of $68.54 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. View Supernus Pharmaceuticals' Earnings History.
Where is Supernus Pharmaceuticals' stock going? Where will Supernus Pharmaceuticals' stock price be in 2017?
6 equities research analysts have issued twelve-month price objectives for Supernus Pharmaceuticals' shares. Their predictions range from $45.00 to $51.00. On average, they anticipate Supernus Pharmaceuticals' stock price to reach $48.17 in the next twelve months. View Analyst Ratings for Supernus Pharmaceuticals.
What are analysts saying about Supernus Pharmaceuticals stock?
Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, "Interim look at SPN-810 Phase 3 program leads to elimination of the low dose. SUPN announced that an interim analysis of the ongoing Phase 3 trials (CHIME 1 and CHIME 2) in impulsive aggression (IA) resulted in the decision to discontinue the low dose arm, 18mg daily, and randomization of future clinical trial subjects to receive either placebo or 36mg per day." (9/19/2017)
- 2. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (7/18/2017)
- 3. Jefferies Group LLC analysts commented, "Following Monday's Zydus settlement, SUPN reached a similar agreement with TEVA on the Trokendi XR (TXR) patent challenge ' allowing generic entry starting January 2023. There is now much more certainty in SUPN's ability to maintain cash flows from 76% of its current epilepsy franchises at least through 2022 and another 24% through 2027 (OXR), bridging to the latestage pipeline, which should come online in 2020. Importantly, SUPN fits with our M&A thesis." (3/8/2017)
Who are some of Supernus Pharmaceuticals' key competitors?
Some companies that are related to Supernus Pharmaceuticals include Mallinckrodt PLC (MNK), Advanced Accelerator Applications S.A. (AAAP), Indivior PLC (INDV), Repligen Corporation (RGEN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Aimmune Therapeutics (AIMT), Eagle Pharmaceuticals (EGRX), Assembly Biosciences (ASMB), Rockwell Medical (RMTI), Novan (NOVN), Check-Cap (CHEK), CorMedix (CRMD), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).
Who are Supernus Pharmaceuticals' key executives?
Supernus Pharmaceuticals' management team includes the folowing people:
- Charles W. Newhall III, Independent Chairman of the Board
- Jack A. Khattar, President, Chief Executive Officer, Secretary, Director
- Gregory S. Patrick, Chief Financial Officer, Vice President
- Stefan K. F. Schwabe M.D. Ph.D., Executive Vice-President - Research and Development, Chief Medical Officer
- Padmanabh P. Bhatt Ph.D., Senior Vice President - Intellectual Property, Chief Scientific Officer
- Victor Vaughn, Senior Vice President - Sales and Marketing
- Georges Gemayel Ph.D., Independent Director
- Frederick M. Hudson CPA, Independent Director
- William A. Nuerge, Independent Director
- John M. Siebert Ph.D., Independent Director
Who owns Supernus Pharmaceuticals stock?
Supernus Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.31%), Vanguard Group Inc. (6.93%), Acadian Asset Management LLC (3.10%), Bank of New York Mellon Corp (3.08%), State Street Corp (2.76%) and Rice Hall James & Associates LLC (2.71%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, M James Barrett, Padmanabh P Bhatt and Stefan KF Schwabe. View Institutional Ownership Trends for Supernus Pharmaceuticals.
Who sold Supernus Pharmaceuticals stock? Who is selling Supernus Pharmaceuticals stock?
Supernus Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Falcon Point Capital LLC, Northpointe Capital LLC, BNP Paribas Arbitrage SA, Bank of New York Mellon Corp, Cornerstone Capital Management Holdings LLC., Fiera Capital Corp, Menta Capital LLC and Gotham Asset Management LLC. Company insiders that have sold Supernus Pharmaceuticals stock in the last year include Gregory S Patrick, Padmanabh P Bhatt and Stefan KF Schwabe. View Insider Buying and Selling for Supernus Pharmaceuticals.
Who bought Supernus Pharmaceuticals stock? Who is buying Supernus Pharmaceuticals stock?
Supernus Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, Hodges Capital Management Inc., Rice Hall James & Associates LLC, Royal Bank of Canada, Mesirow Financial Investment Management Equity Management and Prudential Financial Inc.. View Insider Buying and Selling for Supernus Pharmaceuticals.
How do I buy Supernus Pharmaceuticals stock?
Shares of Supernus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Supernus Pharmaceuticals' stock price today?
One share of Supernus Pharmaceuticals stock can currently be purchased for approximately $36.75.
MarketBeat Community Rating for Supernus Pharmaceuticals (NASDAQ SUPN)MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Supernus Pharmaceuticals (NASDAQ:SUPN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Hold Ratings, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $48.17 (31.07% upside) |
Analysts' Ratings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/21/2017 | Cowen and Company | Reiterated Rating | Buy | $50.00 | Low |  |
| 9/20/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $51.00 | High | |
| 9/20/2017 | Janney Montgomery Scott | Reiterated Rating | Hold | $47.00 | Low | |
| 9/19/2017 | Stifel Nicolaus | Downgrade | Buy -> Hold | $47.00 | High | |
| 9/19/2017 | Cantor Fitzgerald | Reiterated Rating | Buy | $49.00 | High | |
| 9/8/2017 | Piper Jaffray Companies | Reiterated Rating | Hold | $45.00 | Medium | |
| 7/18/2016 | Northland Securities | Downgrade | Outperform -> Market Perform | $24.00 | N/A | |
(Data available from 9/21/2015 forward)
Earnings History for Supernus Pharmaceuticals (NASDAQ:SUPN)Earnings History by Quarter for Supernus Pharmaceuticals (NASDAQ SUPN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/2/2017 | Q2 2017 | $0.24 | $0.32 | $68.54 million | $75.83 million | View | Listen | |
| 5/9/2017 | Q1 2017 | $0.22 | $0.19 | $57.91 million | $57.58 million | View | Listen | |
| 8/2/2016 | Q2 | $0.13 | $0.18 | $49.67 million | $50.40 million | View | Listen | |
| 5/3/2016 | Q1 | $0.09 | $0.08 | $45.33 million | $43.00 million | View | Listen | |
| 3/2/2016 | Q4 | $0.06 | $0.14 | $42.93 million | $42.70 million | View | Listen | |
| 11/3/2015 | Q315 | $0.02 | $0.08 | $37.93 million | $38.60 million | View | Listen | |
| 8/5/2015 | Q215 | $0.02 | $0.03 | $34.07 million | $35.10 million | View | Listen | |
| 5/5/2015 | | $0.02 | $0.02 | $29.16 million | $28.13 million | View | Listen | |
| 11/11/2014 | Q314 | $0.36 | $0.39 | $43.10 million | $52.50 million | View | N/A | |
| 8/11/2014 | Q214 | ($0.16) | $0.08 | $19.85 million | $29.67 million | View | N/A | |
| 5/12/2014 | Q114 | ($0.41) | ($0.38) | $9.94 million | $9.00 million | View | N/A | |
| 3/12/2014 | Q413 | ($0.55) | ($0.65) | $7.78 million | $10.30 million | View | N/A | |
| 11/12/2013 | Q313 | ($0.67) | ($0.78) | $2.54 million | $1.26 million | View | Listen | |
| 8/13/2013 | Q2 2013 | ($0.65) | ($0.89) | $0.91 million | $0.28 million | View | N/A | |
| 11/7/2012 | Q312 | ($0.62) | ($0.55) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)2017 EPS Consensus Estimate: $0.97
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $0.16 | $0.24 | $0.20 |
| Q2 2017 | 2 | $0.23 | $0.25 | $0.24 |
| Q3 2017 | 2 | $0.27 | $0.29 | $0.28 |
| Q4 2017 | 2 | $0.23 | $0.26 | $0.25 |
(Data provided by Zacks Investment Research)
Dividend History for Supernus Pharmaceuticals (NASDAQ:SUPN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Supernus Pharmaceuticals (NASDAQ:SUPN)Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 95.38%
Insider Trades by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/8/2017 | Gregory S. Patrick | CFO | Sell | 50,000 | $47.60 | $2,380,000.00 | |
| 9/8/2017 | Padmanabh P Bhatt | SVP | Sell | 5,000 | $49.86 | $249,300.00 | |
| 9/7/2017 | Stefan K.F. Schwabe | Insider | Sell | 95,000 | $46.59 | $4,426,050.00 | |
| 8/16/2017 | Padmanabh P Bhatt | VP | Sell | 3,709 | $45.23 | $167,758.07 | |
| 7/12/2017 | Padmanabh P Bhatt | VP | Sell | 3,735 | $44.90 | $167,701.50 | |
| 6/23/2017 | Padmanabh P Bhatt | VP | Sell | 2,556 | $44.90 | $114,764.40 | |
| 6/2/2017 | Padmanabh P Bhatt | VP | Sell | 10,000 | $39.86 | $398,600.00 | |
| 5/26/2017 | Padmanabh P Bhatt | VP | Sell | 2,500 | $35.90 | $89,750.00 | |
| 5/25/2017 | Padmanabh P Bhatt | VP | Sell | 5,500 | $34.90 | $191,950.00 | |
| 4/24/2017 | Gregory S Patrick | CFO | Sell | 54,000 | $32.37 | $1,747,980.00 | |
| 4/24/2017 | Padmanabh P Bhatt | VP | Sell | 11,806 | $32.59 | $384,757.54 | |
| 9/16/2016 | Gregory S Patrick | CFO | Sell | 2,000 | $25.00 | $50,000.00 | |
| 7/14/2016 | Gregory S. Patrick | CFO | Sell | 3,395 | $22.00 | $74,690.00 | |
| 4/11/2016 | Padmanabh P Bhatt | VP | Sell | 30,762 | $16.49 | $507,265.38 | |
| 12/9/2015 | Padmanabh P. Bhatt | VP | Sell | 14,238 | $14.90 | $212,146.20 | |
| 12/8/2015 | M James Barrett | Director | Sell | 212,970 | $14.56 | $3,100,843.20 | |
| 11/25/2015 | M James Barrett | Director | Sell | 16,179 | $16.35 | $264,526.65 | |
| 11/18/2015 | M James Barrett | Director | Sell | 93,000 | $16.61 | $1,544,730.00 | |
| 11/16/2015 | M James Barrett | Director | Sell | 119,650 | $16.24 | $1,943,116.00 | |
| 11/4/2015 | Padmanabh P Bhatt | VP | Sell | 5,000 | $19.90 | $99,500.00 | |
| 7/16/2015 | Gregory S Patrick | CFO | Sell | 6,217 | $20.00 | $124,340.00 | |
| 7/13/2015 | Stefan K.F. Schwabe | EVP | Sell | 1,950 | $19.23 | $37,498.50 | |
| 6/17/2015 | M James Barrett | Director | Sell | 111,881 | $16.39 | $1,833,729.59 | |
| 6/17/2015 | Scott D Sandell | Major Shareholder | Sell | 136,597 | $16.50 | $2,253,850.50 | |
| 6/16/2015 | M James Barrett | Director | Sell | 55,105 | $16.85 | $928,519.25 | |
| 6/16/2015 | Scott D Sandell | Major Shareholder | Sell | 95,437 | $16.92 | $1,614,794.04 | |
| 6/12/2015 | Stefan K.F. Schwabe | EVP | Sell | 2,051 | $18.27 | $37,471.77 | |
| 6/11/2015 | Stefan K.F. Schwabe | EVP | Sell | 3,631 | $16.39 | $59,512.09 | |
| 3/24/2015 | Jones W Bryan | VP | Sell | 1,900 | $12.00 | $22,800.00 | |
| 8/19/2013 | Padmanabh Bhatt | VP | Sell | 2,285 | $8.21 | $18,759.85 | |
| 3/22/2013 | Michael Bigham | Director | Buy | 35,000 | $5.41 | $189,350.00 | |
| 3/21/2013 | John M Siebert | Director | Buy | 3,000 | $5.50 | $16,500.00 | |
| 3/15/2013 | Jack A Khattar | CEO | Buy | 10,000 | $6.15 | $61,500.00 | |
| 3/14/2013 | Gregory S Patrick | CFO | Buy | 5,000 | $6.95 | $34,750.00 | |
| 12/4/2012 | John M Siebert | Director | Buy | 7,000 | $8.14 | $56,980.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Supernus Pharmaceuticals (NASDAQ:SUPN)
Latest Headlines for Supernus Pharmaceuticals (NASDAQ:SUPN)
| Source: |
|
| Date | Headline |
|---|
 | Supernus Pharmaceuticals, Inc. (SUPN) Rating Reiterated by Cowen and Company
www.americanbankingnews.com - September 21 at 4:28 PM |
| Janney Montgomery Scott Reaffirms Hold Rating for Supernus Pharmaceuticals, Inc. (SUPN)
www.americanbankingnews.com - September 20 at 6:24 PM |
| Supernus Pharmaceuticals, Inc. (SUPN) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - September 20 at 5:46 PM |
 | Supernus Pharmaceuticals Inc. (SUPN) Sank To A 3-Month Low
www.rttnews.com - September 20 at 9:39 AM |
 | Why Supernus Pharmaceuticals' Shares Plummeted 23.4% Today
finance.yahoo.com - September 20 at 9:39 AM |
| Today's Research Reports on Stocks to Watch: Capricor Therapeutics and Supernus Pharmaceuticals
finance.yahoo.com - September 20 at 9:39 AM |
| Supernus Pharmaceuticals Inc (SUPN) Downgraded to Hold at Stifel Nicolaus
www.americanbankingnews.com - September 20 at 12:46 AM |
 | Supernus Pharma (SUPN) Reports Update on SPN-810 Phase III Clinical Trials
www.streetinsider.com - September 19 at 8:11 AM |
| Supernus Pharmaceuticals Inc. (SUPN) Is Falling After Study Update
www.rttnews.com - September 19 at 8:11 AM |
| Supernus Provides Update on SPN-810 Phase III Clinical Trials
finance.yahoo.com - September 19 at 8:11 AM |
| Supernus shares decline on drug study change
finance.yahoo.com - September 19 at 8:11 AM |
| Comparing Supernus Pharmaceuticals (SUPN) and Its Rivals
www.americanbankingnews.com - September 17 at 8:30 PM |
| Supernus Pharmaceuticals, Inc. (SUPN) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - September 16 at 4:54 PM |
| Zacks: Analysts Anticipate Supernus Pharmaceuticals, Inc. (SUPN) Will Announce Quarterly Sales of $77.74 Million
www.americanbankingnews.com - September 15 at 9:48 AM |
| Stefan K.F. Schwabe Sells 95,000 Shares of Supernus Pharmaceuticals, Inc. (SUPN) Stock
www.americanbankingnews.com - September 11 at 10:20 PM |
| Insider Selling: Supernus Pharmaceuticals, Inc. (SUPN) CFO Sells 50,000 Shares of Stock
www.americanbankingnews.com - September 11 at 10:20 PM |
| Supernus Pharmaceuticals, Inc. (SUPN) SVP Sells $249,300.00 in Stock
www.americanbankingnews.com - September 11 at 10:20 PM |
| Supernus Pharmaceuticals, Inc. (SUPN) Given "Hold" Rating at Piper Jaffray Companies
www.americanbankingnews.com - September 9 at 3:06 PM |
 | Technical Snapshots for These Generic Drugs Stocks -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma, and Lannett
www.prnewswire.com - September 5 at 8:55 AM |
| Reviewing Advanced Accelerator Applications (AAAP) and Supernus Pharmaceuticals (SUPN)
www.americanbankingnews.com - September 3 at 8:30 PM |
| Reviewing Supernus Pharmaceuticals (SUPN) & AbbVie (ABBV)
www.americanbankingnews.com - August 30 at 12:18 PM |
| Supernus Pharmaceuticals, Inc. (SUPN) Expected to Announce Quarterly Sales of $77.74 Million
www.americanbankingnews.com - August 27 at 3:34 AM |
| Brokerages Expect Supernus Pharmaceuticals Inc (SUPN) Will Announce Earnings of $0.27 Per Share
www.americanbankingnews.com - August 25 at 4:28 PM |
 | Is Supernus Becoming The Leader In ADHD Non-Stimulants? - Seeking Alpha
seekingalpha.com - August 24 at 1:30 PM |
| Supernus Pharmaceuticals, Inc. (SUPN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 22 at 4:36 PM |
| Supernus Pharmaceuticals, Inc. (SUPN) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - August 20 at 9:56 AM |
 | Rockville's Supernus Pharmaceuticals wins patents dispute trial
www.bizjournals.com - August 19 at 7:54 AM |
| Contrasting AbbVie (ABBV) and Supernus Pharmaceuticals (SUPN)
www.americanbankingnews.com - August 19 at 6:34 AM |
| Form 8-K SUPERNUS PHARMACEUTICALS For: Aug 15
www.streetinsider.com - August 18 at 7:36 AM |
| Padmanabh P. Bhatt Sells 3,709 Shares of Supernus Pharmaceuticals, Inc. (SUPN) Stock
www.americanbankingnews.com - August 16 at 10:44 PM |
| Supernus Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SUPN-US : August 15, 2017
finance.yahoo.com - August 16 at 7:54 AM |
| Supernus Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SUPN) : August 15, 2017
finance.yahoo.com - August 16 at 7:54 AM |
 | Supernus Defeats Second Generic Challenger to Oxtellar XR®
feeds.benzinga.com - August 15 at 5:23 PM |
| Analysts Set Expectations for Supernus Pharmaceuticals, Inc.'s Q4 2017 Earnings (SUPN)
www.americanbankingnews.com - August 14 at 6:20 AM |
| See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
finance.yahoo.com - August 10 at 8:25 AM |
| FY2019 Earnings Forecast for Supernus Pharmaceuticals, Inc. Issued By Jefferies Group (NASDAQ:SUPN)
www.americanbankingnews.com - August 9 at 2:32 PM |
| Cantor Fitzgerald Analysts Lower Earnings Estimates for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
www.americanbankingnews.com - August 9 at 8:36 AM |
| Zacks: Brokerages Anticipate Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Will Post Quarterly Sales of $76.19 Million
www.americanbankingnews.com - August 9 at 7:44 AM |
| Q3 2017 EPS Estimates for Supernus Pharmaceuticals, Inc. Increased by Analyst (SUPN)
www.americanbankingnews.com - August 8 at 7:08 AM |
| Supernus Pharmaceuticals, Inc. (SUPN) Expected to Announce Earnings of $0.26 Per Share
www.americanbankingnews.com - August 7 at 8:54 AM |
| Piper Jaffray Companies Reiterates Neutral Rating for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
www.americanbankingnews.com - August 5 at 4:18 PM |
| Supernus Pharmaceuticals' (SUPN) CEO Jack Khattar on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 5 at 7:30 AM |
| Jefferies Group LLC Reaffirms "Buy" Rating for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
www.americanbankingnews.com - August 5 at 7:14 AM |
 | Supernus Announces Record Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 4 at 8:40 AM |
| Edited Transcript of SUPN earnings conference call or presentation 3-Aug-17 1:00pm GMT
finance.yahoo.com - August 4 at 8:40 AM |
| Supernus Pharmaceuticals, Inc. (SUPN) Issues Earnings Results
www.americanbankingnews.com - August 3 at 9:21 PM |
| Supernus Announces Record Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 7:40 AM |
| Supernus tops Street 2Q forecasts
finance.yahoo.com - August 3 at 7:40 AM |
| BidaskClub Lowers Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to Hold
www.americanbankingnews.com - August 2 at 7:32 PM |
| SunTrust Banks Weighs in on Supernus Pharmaceuticals, Inc.'s Q2 2017 Earnings (NASDAQ:SUPN)
www.americanbankingnews.com - August 2 at 7:32 AM |
Supernus Pharmaceuticals (SUPN) Chart for Thursday, September, 21, 2017
